Benfotiamine

Phase 3Small molecule

RRuhr University of Bochum

Benfotiamine is one of 4 small molecule programs targeting Diabetic Peripheral Neuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic Peripheral NeuropathyRecruiting

Diabetic Peripheral NeuropathyPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Diabetic Peripheral Neuropathy

#DrugCompanyPhaseTrials

Benfotiamine

RRuhr University of Bochum

Phase 3

1 2

Cymbalta

Jazz Pharmaceuticals

Preclinical

1 3

Mecobalamin

Eisai

Preclinical

1 4

Alpha Lipoic Acid

NNational Center for Complementary and Integrative Health (NCCIH)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

ApprovedRecruiting

Diabetic Peripheral Neuropathy

NCT07708233

Clinical

Trials by Indication[1]

Type 1 Diabetic1 trial

Effects of Vitamin B1 in Type 1 Diabetic Patients

Completed·UUniversity Hospital, Aker·Phase 1/2·NCT00117026·67 enrolled

Type 2 Diabetes Mellitus1 trial

Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus

Unknown status·RRuhr University of Bochum·Phase 4·NCT00446810·30 enrolled

TIA1 trial

Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)

Unknown status·DDiabetes Schwerpunktpraxis·Phase 3·NCT01868191·22 enrolled

Vascular Dysfunction1 trial

Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers

Completed·RRuhr University of Bochum·Phase 3·NCT00785460·20 enrolled

Alzheimer's Disease1 trial

Benfotiamine in Alzheimer's Disease: A Pilot Study

Completed·—·Phase 2·NCT02292238·71 enrolled

3 more indications

Alcohol Use1 trial

High Dose Vitamin B1 to Reduce Abusive Alcohol Use

Completed·UUniversity of Kansas·Phase 4·NCT00680121·120 enrolled

Diabetic Nephropathy1 trial

Benfotiamine in Diabetic Nephropathy

Completed·UUniversity Medical Center Groningen·Phase 4·NCT00565318·86 enrolled

Diabetic Peripheral Neuropathy1 trial

A 12-Week Double-blind Randomized Controlled Study; Comparing the Efficacy of Benfotiamine and Vitamin b1-6-12 in Alleviating Numbness, Sensory Neuropathy Symptoms and Pain in Patients With Diabetic Peripheral Neuropathy

Recruiting·TThammasat University·Approved·NCT07708233·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Benfotiamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Benfotiamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Benfotiamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ruhr University of Bochum company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRuhr University of Bochum

Benfotiamine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Type 1 Diabetic1 trial

Type 2 Diabetes Mellitus1 trial

TIA1 trial

Vascular Dysfunction1 trial

Alzheimer's Disease1 trial

Alcohol Use1 trial

Diabetic Nephropathy1 trial

Diabetic Peripheral Neuropathy1 trial

References

Drug Info

Quick Facts

Related News